Immuneering (IMRX) Cash & Current Investments (2020 - 2024)
Historic Cash & Current Investments for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $50.7 million.
- Immuneering's Cash & Current Investments fell 4790.58% to $50.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $50.7 million, marking a year-over-year decrease of 4790.58%. This contributed to the annual value of $85.7 million for FY2023, which is 1881.94% down from last year.
- According to the latest figures from Q3 2024, Immuneering's Cash & Current Investments is $50.7 million, which was down 4790.58% from $59.7 million recorded in Q2 2024.
- Over the past 5 years, Immuneering's Cash & Current Investments peaked at $149.5 million during Q3 2021, and registered a low of $37.1 million during Q4 2020.
- Its 5-year average for Cash & Current Investments is $96.0 million, with a median of $97.2 million in 2023.
- Per our database at Business Quant, Immuneering's Cash & Current Investments skyrocketed by 30226.14% in 2021 and then tumbled by 4790.58% in 2024.
- Over the past 5 years, Immuneering's Cash & Current Investments (Quarter) stood at $37.1 million in 2020, then soared by 302.26% to $149.2 million in 2021, then decreased by 29.27% to $105.5 million in 2022, then fell by 18.82% to $85.7 million in 2023, then tumbled by 40.87% to $50.7 million in 2024.
- Its Cash & Current Investments stands at $50.7 million for Q3 2024, versus $59.7 million for Q2 2024 and $71.3 million for Q1 2024.